Pharmaceutical

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.

Dec 22, 2023 - 18:00
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

Next Article

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vinod Khosla’s bold AI prediction, digital therapeutics trial updates, & funding for AI in pharma

Vinod Khosla’s bold AI prediction, digital therapeutics...

May 5, 2023

Supreme Court backs Sanofi in high-profile cholesterol drug suit with Amgen

Supreme Court backs Sanofi in high-profile cholesterol ...

May 20, 2023

(Curcumin + doxorubicin) by Immix BioPharma for Colorec...

Dec 24, 2023